AI Generated Image
FDA Approves First mRNA Flu Vaccine For Older Adults
Forbes • • general
Key Points:
- The U.S. FDA has approved the first mRNA-based flu vaccine, mFLUSIVA, for older adults, marking a significant advancement in flu prevention using mRNA technology.
- Moderna CEO Stéphane Bancel highlighted the approval as an important new option for seniors and a testament to the ongoing potential of mRNA platforms.
- Earlier in the year, the FDA initially rejected Moderna’s application due to concerns over the comparator vaccine used in trials, a decision influenced by Dr. Vinay Prasad, a critic of mRNA vaccines and supporter of Robert F. Kennedy Jr.
- The FDA later reversed its stance, with Commissioner Marty Makary describing the initial refusal as part of normal discussions with drug makers.
- This approval comes amid controversy, as Robert F. Kennedy Jr.-led HHS has been scaling back mRNA vaccine development funding, citing concerns over their effectiveness against respiratory infections and promoting alternative vaccine platforms.
